FDA to pull common but ineffective cold medicine from market

The Food and Drug Administration announced Wednesday that it would question to propulsion a widely utilized ingredient successful cough and acold medicines from the market, aft the agency's scientists concluded that the oral mentation of the cause is ineffective arsenic a nasal decongestant.

The FDA's connection comes much than a twelvemonth aft the agency's extracurricular advisers voted against continued usage of the ingredient, called oral phenylephrine, citing concerns with the archetypal information utilized to enactment its support and caller information questioning its effectiveness.

A fig of communal over-the-counter nasal decongestants person relied connected phenylephrine unsocial oregon successful operation with different ingredients for years, including immoderate acold and cough versions of Advil, NyQuil, Sudafed, Robitussin, Tylenol and Theraflu.

"Based connected our reappraisal of disposable data, and accordant with the proposal of the advisory committee, we are taking this adjacent measurement successful the process to suggest removing oral phenylephrine due to the fact that it is not effectual arsenic a nasal decongestant," Dr. Patrizia Cavazzoni, manager of the FDA's Center for Drug Evaluation and Research, said successful a quality release.

The agency's projected order would region oral phenylephrine from the "monograph" of ingredients that drugmakers are allowed to usage successful cough and acold medicines which are sold connected store shelves without a prescription.

The nationalist has until May 7 adjacent twelvemonth to measurement successful connected the proposal. After that remark period, if the FDA decides to finalize its connection to revoke oral phenylephrine's presumption arsenic "generally recognized arsenic harmless and effective," over-the-counter drugmakers would beryllium forced to halt utilizing the ingredient.

"The FDA would supply manufacturers with due clip to either reformulate drugs containing oral phenylephrine oregon region specified drugs from the market," the bureau said successful its release.

The Consumer Healthcare Products Association said Thursday it was "disappointed" successful the FDA's proposal. The manufacture commercialized radical renewed its assertion that nary changes "are warranted" for oral phenylephrine and cited erstwhile FDA and advisory committee decisions that did not telephone for pulling the ingredient.

"PE should stay an disposable enactment for consumers, due to the fact that Americans merit the enactment to take the harmless and effectual OTC medicines they similar and trust on," Scott Melville, CHPA's president and CEO, said successful a statement.

After the FDA's advisory committee past year, pharmacy chain CVS said it would pull any products connected its shelves that lone contained the product.

Spokespeople for drugmakers down the brands did not instantly respond to requests for comment. 

The FDA's connection caps a propulsion by pharmacy professors astatine the University of Florida who have urged the bureau for years to propulsion the product, pointing to caller information showing phenylephrine did nary amended than a placebo erstwhile swallowed.

The latest information shows that lone a tiny fraction of phenylephrine is absorbed into the assemblage erstwhile digested from a pill oregon syrup containing phenylephrine. This is antithetic from different formulations similar the inhaled nasal spray versions of the drug, wherever larger percentages of the cause tin marque it into the bloodstream.

The researchers besides person questioned the archetypal studies that were tally to beryllium the drug's effectiveness, though they admit that it is harmless astatine presently approved levels.

"Let maine beryllium clear, oral phenylephrine is not a information risk," Hatton, a prof astatine the University of Florida, told CBS News past year. "It conscionable doesn't work."

In a technological review published this week by the FDA, the agency's scientists concluded that past studies estimating that higher percentages of the cause could beryllium absorbed during digestion were "an overestimate and based connected outdated technology."

Less than 1% of the cause is absorbed into the bloodstream aft being swallowed, they estimated. Far higher doses could "be needed to execute a clinically meaningful result which would rise important questions astir safety."

"Furthermore, determination are nary objective information demonstrating that oral PE is effectual arsenic a nasal decongestant astatine immoderate dosage," the FDA's scientists wrote.

In:
• Food and Drug Administration